Six weeks of LED blue light device treatment found to be safe and effective for moderate to severe acne
THURSDAY, Sept. 8, 2016 (HealthDay News) — The KLOX BioPhotonic System LED blue light device using specific photo-converter chromophores is safe and efficacious for acne vulgaris, according to a study published online Aug. 30 in the International Journal of Dermatology.
Christina Antoniou, M.D., from the University of Athens in Greece, and colleagues randomly selected one patient hemiface to receive six weeks of twice-weekly treatment with the LED light and the photo-converter chromophores, while the contralateral hemiface was not treated. All patients were provided with a skin cleanser and non-comedogenic cream with ultraviolet protection to be used on the entire face. Patients were followed for an additional six weeks after completion of the six-week treatment period.
The researchers found that 51.7 percent of the patients had a reduction of at least two grades in the Investigator’s Global Assessment (IGA) scale at week 12. Patients with a baseline IGA grade of 3 and 4 had a success rate (grade drop of 2 or more) of 45.3 and 61.1 percent, respectively, at 12 weeks. These results were confirmed in acne inflammatory lesion counts, with a reduction of at least 40 percent in 81.6 percent of treatment hemifaces after 12 weeks. Treatment was safe and well tolerated, with no serious adverse events.
“The BioPhotonic System comprised of LED blue-light phototherapy and photo-converter chromophores was found to be efficacious and safe, with a sustained clinical response at 12 weeks,” the authors write.
Two authors disclosed ties to KLOX Technologies, which funded the trial.
Copyright © 2016 HealthDay. All rights reserved.
